Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003503 | 0.81 | MTNR1A (0.60) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL8274633 | 0.81 | CA2 (0.55) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL2093816 | 0.81 | CA2 (0.55) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL7146984 | 0.81 | CA2 (0.55) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL4605763 | 0.81 | CYP2A6 (0.64) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL2114201 | 0.81 | MTNR1A (0.52) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL413347 | 0.80 | MAPT (0.45) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL4255979 | 0.79 | CYP2A6 (0.71) | CA2CYP2A6MAPTTP53KEAP1 | |
| SCHEMBL8435339 | 0.79 | MTNR1A (0.61) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL8586113 | 0.79 | MTNR1A (0.57) | CA2MTNR1AMTNR1BCYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-1966134-B1 | NOVEL FUSED PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-8158655-B2 | Chymase inhibitors; to treat allergic, inflammatory and fibrotic diseases; 5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonic acid (4-bromo-2-trifluoromethyl-phenyl)-amide | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2118062-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| WO-2007068621-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| EP-0761666-A2 | Antidepressant 1-arylalkyl-4-(alkoxypyridinyl)- or 4-(alkoxypyrimidinyl)piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142452-A1 | Fused pyrrole derivatives | CMA1, PREP, CPA3 | CA2 121/4885MTNR1A 147/4885MTNR1B 259/4885 |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | CA2 4730/4885MTNR1A 3272/4885MTNR1B 3039/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CA2 1127/4885MTNR1A 910/4885MTNR1B 1131/4885 |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | CMA1, ARSA, TPSAB1 | CA2 17/4885MTNR1A 568/4885MTNR1B 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.